AFORRD: Atorvastatin and Omega-3 Fatty Acids in Type 2 Diabetes

Phase 4, randomised, double-blind trial of atorvastatin and omega-3 fatty acid in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Viatris. Primary endpoints: Proportion of patients achieving LDL cholesterol < 2.6 mmol/L (<100 mg/dl) at 16 weeks and Proportion of patients achieving triglycerides < 1.5 mmol/L (<200 mg/dl) at 16 weeks. Started Nov 2004; status: completed.